Evaluation of Drug-Drug Interaction Potential of Probuphine® Implants using a Physiologically-Based Pharmacokinetic Model
Presented by Titan Pharmaceuticals at the 10th American Conference on Pharmacometrics in Orlando, Florida, October 2019.
Posters
Population Pharmacokinetic Modeling and Exposure-Response Analysis of Probuphine® Implants in Opioid Use Disorder Subjects
Presented by Titan Pharmaceuticals at the 10th American Conference on Pharmacometrics in Orlando, Florida, October 2019.
Long-Term Sustained Delivery Of Liothyronine (L-T3) With Subdermal ProNeura™ Implants
Presented by Titan Pharmaceuticals at the 87th annual conference of the American Thyroid Association in Victoria, British Columbia, Canada, October 2017.
Developing Long-term Malarial Chemoprophylactic Compound Releasing Implants
Presented at the Asia Pacific Military Health Exchange (APMHE), Singapore, May 2017.
Nonclinical Dose-escalating Study of ProNeura Continuous Drug Delivery Platform in Parkinson's Disease
Presented by Titan Pharmaceuticals at the Movement Disorder Society (MDS) 19th International Congress of Parkinson's Disease and Movement Disorders, San Diego, California, June 2015.
Buprenorphine Implants for the Maintenance Treatment of Opioid Dependence: Twelve Month Outcomes
Presented at the American Association for the Treatment of Opioid Dependence conference in Philadelphia, Pennsylvania, November 2013.
Results of a Six-Month, Randomized, Controlled, Phase-3 Trial Comparing the Efficacy and Safety of Buprenorphine Implants to Placebo Implants, and Sublingual Buprenorphine/Naloxone for Opioid Addiction.
Presented at the American Society of Addiction Medicine (ASAM), Atlanta, Georgia, April 2012.
Results of a Six-Month, Randomized, Controlled, Phase 3 Trial Comparing the Efficacy and Safety Of Probuphine™ to Placebo Implants, and Suboxone® for Opioid Addiction
Presented by Titan Pharmaceuticals at the 13th annual meeting of International Society of Addiction Medicine (ISAM), Oslo, Norway, September 2011.
Safety, Efficacy, and Pharmacokinetics of Probuphine®, a 6-Month Implantable Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Addiction
Presented by Titan Pharmaceuticals at American College of Neuropsychopharmacology (ACNP), Hollywood, Florida, December 2009.
Continuous Dopaminergic Stimulation Evaluated in Parkinsonian Animal Model
Presented by Titan Pharmaceuticals at the Society for Neuroscience, New Orleans, Louisiana, November 2003.